Curanex Pharmaceuticals Inc Common Stock
CURXNASDAQHealthcareBiotechnology
Previous close
$4.71
−$0.56 · -10.63%
CURX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
19
Strong Down
Sentiment
53
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCuranex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jun Liu
- Listed since
- Aug 26, 2025
- Employees
- 6
Market position
Day range
Current $4.71
52-week range
Current $4.71
- Open
- $5.10
- Previous close
- $5.27
- Volume
- 28.57K
- 3.87× average
- Average volume
- 7.38K
- Average daily volume
- Market cap
- 6.67M USD
- Beta
- -2.74
- Market reference 1
- 50-day average
- $4.6924
- +0.38% above average
- 200-day average
- $7.1876
- -34.47% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 3.8M USD
- P/E (TTM)
- -0.6×
- P/B (TTM)
- 1.4×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0.9×
- Earnings yield
- -50.14%
- Free cash flow yield
- -124.42%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -37.66%
- Return on assets
- -36.49%
- Return on invested capital
- -36.65%
Financial health
- Debt / equity
- 0.06×
- Current ratio
- 81.93×
- Altman Z-score
- 7.9
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | 26K USD |
| Cost of goods sold | — | — | — | 21.57K USD |
| Gross profit | — | — | — | 4.43K USD |
| Research and development | 2.99M USD | — | — | — |
| Selling, general, and administrative | 1.25M USD | 290.39K USD | 19.3K USD | 24.66K USD |
| Operating expenses | 4.24M USD | 365.06K USD | 19.3K USD | 24.66K USD |
| Interest expense | 8.54K USD | — | — | — |
| Depreciation and amortization | — | — | 1.82K USD | 21.16K USD |
| Operating income | −4.24M USD | −365.06K USD | −19.3K USD | −20.23K USD |
| Net income | −4.23M USD | −361.51K USD | −19.2K USD | −20.23K USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -0.6
EPS: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 20, 2026 | 1:20 | — | — |
Effective Aug 20, 2026
1:20
CURX peers
Continue in GoAI
Research CURXresearch.disclaimer